Evaluation Cutaneous Lupus Erythematosus: Strategies for Diagnosis, Treatment, and Interdisciplinary Management Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Describe the clinical subtypes of CLE and strategies for accurate diagnosis 5 4 3 2 1 Evaluate the most recent efficacy and safety data associated with current and emerging therapies for CLE 5 4 3 2 1 Implement multidisciplinary, patient-centric strategies to select optimal treatment and improve the management of CLE 5 4 3 2 1 Please rate the faculty on the following: Joseph Merola, MD: Knowledge, expertise, and teaching ability 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with CLE do you see during a typical week? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No Which of the following subtypes occurs in a transient nature on areas of the skin that are predominantly exposed to UV radiation or can appear as a general rash? Acute CLE Subacute CLE Chronic CLE Discoid LE Which of the following agents targets ILT7 and is under investigation for CLE and DLE? Afimetoran Branebrutinib Daxdilimab Iberdomide Patient-reported outcomes, such as health-related quality of life and patient global assessment of disease, should be evaluated at what point(s) during treatment? As a baseline parameter during initial visits As a follow-up evaluation after successful treatment initiation During initial baseline visits and at treatment follow-ups If no improvement is seen after treatment initiation How confident are you in your ability to implement novel treatment strategies to improve patient outcomes? Very confident Confident Somewhat confident Not very confident Not at all confident How confident are you in your ability to identify and diagnose CLE subtypes? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often: (select all that apply) Evaluate current and emerging data on novel agents for CLE Employ appropriate screening strategies to accurately diagnose atypical lesions Implement multidisciplinary approaches to improve CLE treatment outcomes Discuss patient goals and values for CLE treatment Utilize novel treatments in clinical practice where appropriate Review guideline updates for optimal CLE management Other (please specify): Previous